-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Bristol-Myers Squibb Company's Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$42.52 B | $46.39 B | $46.16 B | $45.01 B | $48.30 B |
| Cost of Revenue |
|
$20.82 B | $19.62 B | $19.67 B | $19.65 B | $20.87 B |
| Gross Profit |
|
$21.70 B | $26.76 B | $26.49 B | $25.36 B | $27.43 B |
| Research & Development |
|
$9.56 B | $9.53 B | $9.41 B | $9.21 B | $9.78 B |
| Selling,General & Administrative |
|
$7.65 B | $7.69 B | $7.81 B | $7.68 B | $7.99 B |
| Operating Expense |
|
$17.21 B | $17.22 B | $17.22 B | $16.89 B | $17.77 B |
| Operating Income |
|
$4.49 B | $9.54 B | $9.27 B | $8.47 B | $9.66 B |
| Net Income |
|
-$9.00 B | $6.99 B | $6.33 B | $8.03 B | -$8.95 B |
Bristol-Myers Squibb Company's Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$16.45 B | $17.22 B | $9.25 B | $12.28 B | $10.86 B |
| Inventories |
|
$2.07 B | $2.10 B | $2.34 B | $2.66 B | $2.56 B |
| Total Current Assets |
|
$30.19 B | $33.26 B | $27.27 B | $31.77 B | $29.78 B |
| Property,Plant and Equipment |
|
$6.75 B | $6.97 B | $7.48 B | $8.04 B | $8.36 B |
| Goodwill |
|
$20.55 B | $20.50 B | $21.15 B | $21.17 B | $21.72 B |
| Total Assets |
|
$118.48 B | $109.31 B | $96.82 B | $95.16 B | $92.60 B |
| Total Liabilities |
|
$80.60 B | $73.31 B | $65.70 B | $65.67 B | $76.22 B |
| Retained Earnings |
|
$21.28 B | $23.82 B | $25.50 B | $28.77 B | $14.91 B |
| Total Shareholder Equity |
|
$37.82 B | $35.95 B | $31.06 B | $29.43 B | $16.34 B |
| Common Stock |
|
$292.00 M | $292.00 M | $292.00 M | $292.00 M | $292.00 M |
Bristol-Myers Squibb Company's Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$10.38 B | $10.69 B | $10.28 B | $9.76 B | $9.60 B |
| Dividends Payout |
|
-$4.08 B | -$4.40 B | -$4.63 B | -$4.74 B | -$4.86 B |
| Capital Expenditures (Capex) |
|
-$753.00 M | -$973.00 M | -$1.12 B | -$1.21 B | -$1.25 B |
| Free Cash Flow (FCF) |
|
$13.30 B | $15.23 B | $11.95 B | $12.65 B | $13.94 B |
Bristol-Myers Squibb Company's Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$21.70 B | $26.76 B | $26.49 B | $25.36 B | $27.43 B |
| Gross Profit Margin (%) |
|
51.04% | 57.69% | 57.39% | 56.34% | 56.80% |
| Operating Income |
|
$4.49 B | $9.54 B | $9.27 B | $8.47 B | $9.66 B |
| Operating Income Margin (%) |
|
10.56% | 20.57% | 20.08% | 18.82% | 20.00% |
| Net Income |
|
-$9.00 B | $6.99 B | $6.33 B | $8.03 B | -$8.95 B |
| Net Income Margin (%) |
|
-21.16% | 15.08% | 13.71% | 17.83% | -18.53% |
| EBITDA |
|
$4.93 B | $20.12 B | $19.22 B | $19.37 B | $3.17 B |
| EBITDA Margin (%) |
|
11.59% | 43.37% | 41.64% | 43.03% | 6.56% |
Bristol-Myers Squibb Company's Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
-23.78% | 19.46% | 20.37% | 27.27% | -54.78% |
| Return on Assets (ROA) |
|
-7.59% | 6.40% | 6.53% | 8.43% | -9.66% |
| Debt to Equity |
|
136.62% | 126.85% | 131.09% | 140.89% | 313.44% |
| Debt to total asset |
|
43.61% | 41.71% | 42.05% | 43.57% | 55.29% |
| Enterprise value to revenue |
|
4.17 | 3.67 | 4.00 | 3.03 | 3.22 |
| Enterprise value to EBITDA |
|
35.95 | 8.45 | 9.62 | 7.03 | 49.08 |
| Enterprise value |
|
$177.19 B | $170.10 B | $184.85 B | $136.16 B | $155.50 B |
| Cash to Debt |
|
27.19% | 35.54% | 32.09% | 33.43% | 29.67% |
| Tax Rate (%) |
|
-30.91% | 13.39% | 17.74% | 4.74% | -6.61% |
| Payout Ratio |
|
-45.30% | 62.85% | 73.24% | 59.12% | -54.35% |
Frequently Asked Questions
